Analysis of Graves' disease from the origins to the current historical evolution The history of Graves’ disease discovery and treatment

Main Article Content

Lorenzo Mortara
Grace Coco
Lucrezia Gatti
Eliana Piantanida
Daniela Gallo

Keywords

Thyroid, Graves’ disease, autoimmunity, hyperthyroidism, ophthalmopathy, James Graves, Basedow disease

Abstract

Graves' disease (GD), also called Basedow's disease, owe the names respectively to the Irish physician Robert James Graves, who described the disease in 1835, and to Karl Adolph von Basedow, who reported the same clinical picture in Germany in 1840. Indeed, it was the Englishman Caleb Hillier Parry to firstly report a case of hyperthyroidism and goiter in 1786, but his report was not published until 1825. Earlier, in 1802, the Italian physician Giuseppe Flajani, described a disease characterized by the coexistence of palpitations and exophthalmos. Graves' disease is an autoimmune, organ-specific, disorder sustained by auto-antibodies stimulating the thyroid-stimulating hormone (TSH) receptor (R). It is believed that the interaction between susceptible genes and environmental/endogen factor triggers the development of the disease. As a consequence of TSH-R improper stimulation, hyperthyroidism and goiter are the main clinical manifestation of the disease, accompanied, in the 25% of cases, by Graves’ orbitopathy (GO). GD is primarily diagnosed by demonstrating the presence of thyrotoxicosis and the pathognomonic TSH-R antibodies (TSH-RAb). In this manuscript we will refer to the disease as Graves’ disease.

Abstract 362 | PDF Downloads 125

References

References
(1) Smith TJ., Hegedüs L. Graves’ Disease. The New England Journal of Medicine 2016; 375(16), 1552–1565. doi.org/10.1056/NEJMra1510030
(2) Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704–20. doi: 10.1210/clinem/dgaa646
(3) Nabipour I, Burger A, Moharreri M-R, Azizi F. Avicenna. The first to describe thyroid-related orbitopathy. Thyroid 2009; 19: 7-8. Doi: 10.1089/thy.2008.0299
(4) Graves RJ. Clinical lectures delivered at the Meath Hospital during the session 1834–1835. Lecture XII. Newly observed affection of the thyroid. London Med Surg 1835;7:515–523.
(5) Graves RJ. A system of clinical medicine /. Fannin,.1843
(6) Coakley D. Robert Graves, evangelist of clinical medicine. The Irish Endocrine Society 1996; 9-102
(7) Von Basedow KA. Exophthalmos durch hypertrophie des zellgewebesin der Augenhole. Wochenschr Ges Heilk Berl 1840; 6: 197
(8) Testa, A.G (1810). Delle malattie del cuore, loro cagioni, specie, segni e cura. Bologna, Tip. Lucchesini 1810
(9) Flajani G. Sopra un tumor freddo nell’anterior parte del collo broncocele (Osservazione LXVII). Collezione d’osservazioni e reflessioni di Chir, Rome, Milano. A Ripa Press Lino Conte 1802; 3: 270–273
(10) Parry CH. (1825). Collection from the unpublished medical writings of the late Caleb Hiller Parry. Underwoods 1825; 1, 2.
(11) Muller AF., Drexhage, HA., Berghout, A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: Recent insights and consequences for antenatal and postnatal care. Endocrine Reviews 2001. 22(5), 605–630. doi.org/10.1210/edrv.22.5.0441
(12) Winsa B., Adami HO., Bergström R., Gamstedt A., Dahlberg PA., Adamson U., Jansson R., Karlsson A. Stressful life events and Graves’ disease 1991. Lancet (London, England), 338(8781), 1475–1479. https://doi.org/10.1016/0140-6736(91)92298-g
(13) Osler W. The principles and practice of medicine : designed for the use of practitioners and students of medicine. New York : D. Appleton and Co 1898; 3e: 836-837).
(14) Charcot JM. Mèmoire sur une affection caracterisè par des palpitations du Coeur et des artères, la tumefaction de la glande thyroid et une double exophthalmie. C T Mem Soc Biol 1857 3:43.
(15) Trousseau A. Lectures on Clinical Medicine delivered at the HGtel-Dieu, Paris. Lecture XIX. London, New Sydenham Society, 1868, p 542.
(16) Murray, G. Thyroid secretion as a factor in exophthalmic goitre. The Lancet 1893, 142(3663), 1177–1179. doi.org/10.1016/S0140-6736(01)96393-7
(17) Rogers J, & Beebe SV. The treatment of thyroidism by a specific cytotoxic serum. Archives of Internal Medicine 1908, II(4), 297–329. doi.org/10.1001/archinte.1908.00050090002001
(18) Marine D, Lenhart CH: Pathological anatomy of exophthalmic goiter. Arch Intern Med. 1911, 8:265-316
(19) Magner J. Historical Note: Many Steps Led to the ‘Discovery’ of Thyroid-Stimulating Hormone. Eur Thyroid J. 2014;3(2):95-100. doi:10.1159/000360534
(20) Adams DD. The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. The Journal of Clinical Endocrinology and Metabolism 1958, 18(7), 699–712. doi.org/10.1210/jcem-18-7-699
(21) Volpé R. Autoimmunity causing thyroid dysfunction. Endocrinology and Metabolism Clinics of North America 1991, 20(3), 565–587.
(22) Weetman AP. Graves’ disease. The New England Journal of Medicine 2000, 343(17), 1236–1248. doi.org/10.1056/NEJM200010263431707
(23) Oertel JE, LiVolsi VA. Pathology of thyroid diseases. Braverman LE, Utiger RD (eds.), Werner and Ingbar’s The Thyroid a Fundamental Clinical Text 1991.
(24) Lippincott Williams & Wilkens, Tomer, Y., & Davies, T. F. Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function. Endocrine Reviews 2003, 24(5), 694–717. doi.org/10.1210/er.2002-0030
(25) McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinology and Metabolism Clinics of North America 1998, 27(1), 73–89. doi.org/10.1016/s0889-8529(05)70299-1
(26) Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-4659
(27) Ferrari SM, Fallahi P, Antonelli A, Benvenga S. Environmental Issues in Thyroid Diseases. Front Endocrinol (Lausanne). 2017 Mar 20;8:50. doi: 10.3389/fendo.2017.00050. PMID: 28373861; PMCID: PMC5357628.
(28) Gallo, D., Piantanida, E., Badino, P., Mortara, L. The story of a vitamin for bone health that upgraded to hormone for systemic good health. Medicina Historica 2018; 2(3):152-160
(29) Gallo D, Mortara L, Gariboldi MB, Cattaneo SAM, Rosetti S, Gentile L, Noonan DM, Premoli P, Cusini C, Tanda ML, Bartalena L, Piantanida E. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review. J Endocrinol Invest. 2020; 43(4):413-429. doi: 10.1007/s40618-019-01123-5
(30) Kawakami-Tani T, Fukawa E, Tanaka H, Abe Y, Makino I Effect of 1alfa-hydrossivitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves’ disease. Metabolism 1997. 46(10):1184–1188
(31) Poma AM, Hammerstad SS, Genoni A, Basolo A, Dahl-Jorgensen K, Toniolo A. Immune Transcriptome of Cells Infected with Enterovirus Strains Obtained from Cases of Autoimmune Thyroid Disease. Microorganisms. 2021 Apr 19;9(4):876).
(32) Prabhakar BS, Bahn RS, Smith T J. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocrine Reviews 2003, 24(6), 802–835. doi.org/10.1210/er.2002-0020 Philidelphia; 1991: 603–42
(33) Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L. The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016 Dec;39(12):1445-1451. Doi: 10.1007/s40618-016-0516-7
(34) Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: A 2014 update. Journal of Endocrinological Investigation 2014, 37(8), 691–700. doi.org/10.1007/s40618-014-0097-2sawin
(35) Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Front Endocrinol (Lausanne)2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993
(36) Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM. The 2021 european group on Graves' orbitopathy (eugogo) clinical practice guidelines for the medical management of graves' orbitopathy. Eur J Endocrinol. 2021 Jul 1:EJE-21-0479.R1. doi: 10.1530/EJE-21-0479. Epub ahead of print
(37) Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9. doi: 10.1210/jc.2012-3873
(38) Ippolito S, et al. Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021 Aug;44(8):1707-1718. doi: 10.1007/s40618-020-01479-z
(39) Bartalena L, Piantanida E, Tanda ML. Can a patient-tailored treatment approach for Graves' disease reduce mortality? Lancet Diabetes Endocrinol. 2019;7(4):245-246. doi: 10.1016/S2213-8587(19)30057-9
(40) Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen A, Madsen JC, Faber J, Hansen PR, Pedersen OD, Torp-Pedersen C, & Gislason, G. H. The spectrum of thyroid disease and risk of new onset atrial fibrillation: A large population cohort study. BMJ 2012 (Clinical Research Ed.), 345, e7895. doi.org/10.1136/bmj.e7895
(41) Vaidya B, Pearce SHS. Diagnosis and management of thyrotoxicosis. BMJ (Clinical Research Ed.) 2014. doi.org/10.1136/bmj.g5128
(42) Cooper DS. Hyperthyroidism. Lancet 2003(London, England), 362(9382), 459–468. doi.org/10.1016/S0140-6736(03)14073-1
(43) Schwartz KM, Fatourechi V, Ahmed DDF, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): Long-term outcome. The Journal of Clinical Endocrinology and Metabolism 2002, 87(2), 438–446. https://doi.org/10.1210/jcem.87.2.8220
(44) Fatourechi V. Thyroid dermopathy and acropachy. Best Practice & Research. Clinical Endocrinology & Metabolism 2012, 26(4), 553–565. doi.org/10.1016/j.beem.2011.10.001
(45) Fatourechi V, Ahmed DDF, & Schwartz KM. Thyroid acropachy: Report of 40 patients treated at a single institution in a 26-year period. The Journal of Clinical Endocrinology and Metabolism 2002, 87(12), 5435–5441. doi.org/10.1210/jc.2002-020746
(46) Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, & Antonelli A. The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmunity Reviews 2019, 18(3), 287–292. doi.org/10.1016/j.autrev.2018.10.001
(47) Burch HB, Cooper DS. Anniversary review: Antithyroid drug therapy: 70 years later. Eur J Endocrinol. 2018 Oct 12;179(5):R261-R274. doi: 10.1530/EJE-18-0678
(48) Guyotjeannin C. Le souvenir de Bernard Courtois (1777-1838) (In memory of Bernard Courtois (1777-1838)]. Rev Hist Pharm (Paris) 1995;42(305):117-23. French. PMID: 11640457
(49) Coindet JF. Découverte d’un nouveau remède contre le goitre. Bibliothèque Universelle, Sciences et Arts, Genève, 1820, 14, 190-198, and Annales de Chimie et de Physique (Paris), 1820, 15, 49-59
(50) Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163-76. doi: 10.1089/thy.1997.7.163
(51) Chapman EM, Evans RD. The treatment of hyperthyroidism with radioactive iodine. Jama.1946;131(2):86–91. doi:10.1001/jama.1946.02870190010003
(52) Sarkar S, Banerjee S, Sarkar R, Sikder B. A Review on the History of 'Thyroid Surgery'. Indian J Surg. 2016 Feb;78(1):32-6. doi: 10.1007/s12262-015-1317-5
(53) Hartley F. Thyroidectomy for exophthalmic goiter. Ann Surg. 1905;42:33–48. doi: 10.1097/00000658-190507000-00003
(54) Mayo CH. Ligation and partial thyroidectomy for hyperthyroidism. In: Mellish MH, editor. Collected papers by the staff of St. Mary’s Hospital, Mayo Clinic. Rochester: Mayo Clinic; 1910
(55) Smith EM, Phan M, Kruger TE, Coppenhaver DH, Blalock JE. Human lymphocyte production of immunoreactive thyrotropin. Proc Natl Acad Sci USA. (1982) 80:6010–13. doi: 10.1073/pnas.80.19.6010
(56) Wang HC, Drago J, Zhou Q, Klein JR. An intrinsic thyrotropin-mediated pathway of TNFα production by bone marrow cells. Blood. (2003) 101:119– 23. doi: 10.1182/blood-2002-02-0544
(57) De Vito P, Incerpi S, Pedersen JZ, Luly P, Davis FB, Davis PJ. Thyroid hormones as modulators of immune activities at cellular level. Thyroid. (2011) 8:879–90. doi: 10.1089/thy.2010.0429
(58) Mooij P, Simons PJ, de Haan-Meulman M, de Wit HJ, Drexhage HA. Effect of thyroid hormones and other iodinated compounds on the transition of monocytes into veiled/dendritic cells: role of granulocyte-macrophage colony-stimulating factor, tumour-necrosis factor-alpha and interleukin-6. J Endocrinol. (1994) 140:503–12. doi: 10.1677/joe.0.1400503
(59) Dedecjus M, Stasiolek M, Brzezinski J, Selmaj K, Lewinski A. Thyroid hormones influence human dendritic cells’ phenotype, function, subsets distribution. Thyroid. (2010) 21:533–40. doi: 10.1089/thy.2010.0183
(60) Bagriacik EU, Klein JR. The thyrotropin (thyroid stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD43RB high lymph node T cells: functional role of thyroid stimulating hormone during immune activation. J Immunol. (2000) 164:6158– 65. doi: 10.4049/jimmunol.164.12.6158
(61) Landucci E, Laurino A, Cinci L, Gencarelli M, Raimondi L. Thyroid hormone, thyroid hormone metabolites and mast cells: a less explored issue. Front Cell Neurosc. (2019) 13:79. doi: 10.3389/fncel.2019.00079
(62) Coutelier JP, Kehrl JH, Bellur SS, Kohn LD, Notkins AL, Prabhakar BS. Binding and functional effects of thyroid stimulating hormone to human immune cells. J Clin Immunol. (1990) 10:204–10. doi: 10.1007/bf00918653
(63) Whetsell M, Bagriacik EU, Seetharamaiah GS, Prabhakar BS, Klein JR. Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodulating properties. Cell Immunol. (1999) 15:159– 66. doi: 10.1006/cimm.1998.1444
(64) Klein JR. The immune system as a regulator of thyroid hormone activity. Exp Biol Med (Maywood). (2006) 231:229–36. doi: 10.1177/153537020623100301
(65) Kmiec Z, Mysliwska J, Rachon D, Kotlarz G, Sworczak K, Mysliwski A. Natural killer activity and thyroid hormone levels in young and elderly persons. Gerontology. (2001) 47:282–8. doi: 10.1159/000052813 110.
(66) Lee EK, Sunwoo J. NK cells and thyroid disease. Endocrinol Metab. (2019) 34:132–7. doi: 10.3803/EnM.2019.34.2.132
(67) Gallo D, Piantanida E, Gallazzi M, Bartalena L, Tanda ML, Bruno A, Mortara L. Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher. Front Endocrinol (Lausanne). 2020 Jul 17;11:406. doi: 10.3389/fendo.2020.00406
(68) Iwatani Y, Amino N, Kabutomori O, Mori H, Tamaki H, Motoi S, et al. Decrease of peripheral large granular lymphocytes in Graves’ disease. Clin Exp Immunol. (1984) 55:239–44.
(69) Solerte S, Precerutti S, Gazzaruso C, Locatelli E, Zamboni M, Schifino N, et al. Defect of a subpopulation of natural killer immune cells in Graves’ disease and Hashimoto’s thyroiditis: normalizing effect of dehydroepiandrosterone sulfate. Eur J Endocrinol. (2005) 152:703–12. doi: 10.1530/eje.1. 01906
(70) Gallagher TF, Hellman L, Finkelstein J, Yoshida K, Weitzman ED, Roffward HD, et al. Hyperthyroidism and cortisol secretion in man. J Clin End Metab. (1972) 34:919–27. doi: 10.1210/jcem-34-6-919